The contract covers all of Foundation Medicine's genomic profiling tests, including FoundationOne CDx, FoundationOne Liquid, and FoundationOne Heme.
The survey results point to the need for greater education among patients so they can better advocate for themselves.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
Two new studies found that prenatal whole-exome sequencing could uncover clinically significant variants in an additional 8 to 12 percent of fetuses with structural anomalies.
In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.
The test showed 90 percent sensitivity and 75 percent specificity in a 250-patient blinded study, even without the addition of clinical risk information.
As novel findings emerge from these research efforts, the VA is also contemplating how some of these learnings may be communicated to the participants.
A team led by researchers at the NHLBI are testing the efficacy of measuring ddcfDNA in blood as a biomarker of chronic rejection for lung transplants.
At the Precision Medicine World Conference, researchers from Sanford Health, Providence Health, and Israel's Maccabi discussed their genomics programs.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.
NorthShore University HealthSystem is among the first of many interested in implementing genetic testing and tracking the population health impact, according to Color.
After a successful pilot that recruited 1,000 patients, NorthShore will now engage 10,000 people to receive Color's genomic testing in their primary care.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
With the acquisition, Qiagen will integrate N-of-One’s MarkerMine database into its core technology to help customers design new, targeted therapies.
A new analysis found kidney disease-related pathogenic or likely pathogenic variants in exomes for roughly 9 percent of individuals with chronic kidney disease.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.
A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.
Vox writes that lab mishaps involving pathogens are quite common.
In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.